Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Jackson

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Pharmaceuticals (Basel, Switzerland)|September 25, 2019
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and BexxarChristos Sachpekidis, David B Jackson, Theodoros G Soldatos
High-Throughput|November 28, 2018
<i>In Silico</i> Profiling of Clinical Phenotypes for Human Targets Using Adverse Event DataTheodoros G Soldatos, Guillaume Taglang, David B Jackson
Drug Discovery Today. Technologies|July 2, 2014
Microarrays meet the Voltaire challenge: Drug discovery on a chip?David B Jackson, Martin A Stein, Alejandro Merino, et al.
Drug Discovery Today|July 6, 2010
Drug profiling: knowing where it hitsAlejandro Merino, Agnieszka K Bronowska, David B Jackson, et al.
Pharmaceutics|June 28, 2023
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD<sup>3</sup>)David B Jackson, Rebecca Racz, Sarah Kim, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 10, 2022
Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reportsTheodoros G Soldatos, Sarah Kim, Stephan Schmidt, et al.
Journal of the American College of Radiology : JACR|April 7, 2007
Outsourced teleradiology imaging services: an analysis of discordant interpretation in 124,870 casesWilson S Wong, Ivan Roubal, David B Jackson, et al.
Clinical Pharmacology and Therapeutics|October 22, 2020
Target Adverse Event Profiles for Predictive Safety in the Postmarket SettingPeter Schotland, Rebecca Racz, David B Jackson, et al.
Clinical and Translational Science|January 11, 2022
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug developmentSarah Kim, Gezim Lahu, Majid Vakilynejad, et al.
Clinical and Translational Science|February 22, 2022
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitorsSarah Kim, Gezim Lahu, Majid Vakilynejad, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Pharmaceuticals (Basel, Switzerland)|September 25, 2019
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and BexxarChristos Sachpekidis, David B Jackson, Theodoros G Soldatos
High-Throughput|November 28, 2018
<i>In Silico</i> Profiling of Clinical Phenotypes for Human Targets Using Adverse Event DataTheodoros G Soldatos, Guillaume Taglang, David B Jackson
Drug Discovery Today. Technologies|July 2, 2014
Microarrays meet the Voltaire challenge: Drug discovery on a chip?David B Jackson, Martin A Stein, Alejandro Merino, et al.
Drug Discovery Today|July 6, 2010
Drug profiling: knowing where it hitsAlejandro Merino, Agnieszka K Bronowska, David B Jackson, et al.
Pharmaceutics|June 28, 2023
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD<sup>3</sup>)David B Jackson, Rebecca Racz, Sarah Kim, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 10, 2022
Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reportsTheodoros G Soldatos, Sarah Kim, Stephan Schmidt, et al.
Journal of the American College of Radiology : JACR|April 7, 2007
Outsourced teleradiology imaging services: an analysis of discordant interpretation in 124,870 casesWilson S Wong, Ivan Roubal, David B Jackson, et al.
Clinical Pharmacology and Therapeutics|October 22, 2020
Target Adverse Event Profiles for Predictive Safety in the Postmarket SettingPeter Schotland, Rebecca Racz, David B Jackson, et al.
Clinical and Translational Science|January 11, 2022
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug developmentSarah Kim, Gezim Lahu, Majid Vakilynejad, et al.
Clinical and Translational Science|February 22, 2022
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitorsSarah Kim, Gezim Lahu, Majid Vakilynejad, et al.
Pageof 3